Experimental

ApprovedBiologic

Biogen

Experimental is one of 487 biologic programs targeting Albuminuria. It is currently in Approved.

Indications

Total Trials

Active Trials

486

Competitors

Pipeline

Status by Indication[3][1]

Indication

AlbuminuriaActive, not recruiting

Cutaneous LeishmaniasisActive, not recruiting

Esophageal CancerActive, not recruiting

Chronic HepatitisActive, not recruiting

PeritonitisActive, not recruiting

Allergic RhinitisActive, not recruiting

Rotator Cuff TearActive, not recruiting

BursitisActive, not recruiting

Congestive Heart FailureActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

AlbuminuriaApproved

Active, not recruiting

Cutaneous LeishmaniasisPhase 1/Phase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

Chronic HepatitisApproved

Active, not recruiting

PeritonitisApproved

Active, not recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Rotator Cuff TearPreclinical

Active, not recruiting

BursitisPhase 2

Active, not recruiting

Congestive Heart FailurePhase 3

Active, not recruiting

Lung AdenocarcinomaApproved

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Experimental

Biogen

Approved

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Vizimpro

Pfizer

Preclinical

4 7

Gilotrif

Boehringer Ingelheim

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Allergic Rhinitis

NCT07168473

Q1 2027

Phase 1/2Not yet recruiting

Radiotherapy

NCT06195670

Q1 2028

Phase 2Recruiting

Esophageal Cancer

NCT06253650

Q4 2029

Phase 2Recruiting

Patients With Locally Advanced Rectal Cancer

NCT06864013

Phase 3Recruiting

Follicular Lymphoma

NCT05045664

Clinical

Trials by Indication[1]

Peritonitis2 trials

A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis

Terminated·NNYU Langone Health·N/A·NCT02528097·2 enrolled

Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)

Unknown status·WWeill Medical College of Cornell University·Phase 4·NCT00761098·80 enrolled

Esophageal Cancer1 trial

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT06253650·46 enrolled

Osteoporosis1 trial

Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis

Completed·KKorea Health Industry Development Institute·Phase 2·NCT02592161·166 enrolled

Post-cesarean Pain1 trial

Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine

Withdrawn·—·Phase 4·NCT01211431

Clinical Trial1 trial

JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients

Unknown status·—·N/A·NCT03725566·24 enrolled

22 more indications

Radiotherapy1 trial

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Not yet recruiting·ZZhejiang Cancer Hospital·Phase 1/2·NCT06195670·220 enrolled

Allergic Rhinitis1 trial

Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma

Recruiting· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT07168473·274 enrolled

Patients With Locally Advanced Rectal Cancer1 trial

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06864013·116 enrolled

Lung Adenocarcinoma1 trial

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Unknown status·BBetta Pharmaceuticals Co., Ltd.·Phase 4·NCT01665417·100 enrolled

Efficacy1 trial

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

Completed·WWarner Chilcott·Phase 2·NCT00577837·370 enrolled

Congestive Heart Failure1 trial

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL

Unknown status·CCelyad Oncology SA·Phase 3·NCT02317458·400 enrolled

Follicular Lymphoma1 trial

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

Recruiting·HHeidelberg University·Phase 3·NCT05045664·100 enrolled

Chronic Hepatitis1 trial

Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT04539652·78 enrolled

Albuminuria1 trial

Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria

Unknown status·UUniversity of Pavia·Phase 4·NCT01038895·120 enrolled

Septic Shock1 trial

Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study.

Unknown status·NNational Hepatology & Tropical Medicine Research Institute·Phase 2/3·NCT03608514·100 enrolled

Cutaneous Leishmaniasis1 trial

Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.

Withdrawn·UUniversidad de Antioquia·Phase 1/2·NCT04072874

Tolerance1 trial

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

Completed·JJohnson & Johnson Consumer Inc. (J&JCI)·N/A·NCT02357940·41 enrolled

Rotator Cuff Tear1 trial

Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear.

Recruiting·EEulji University Hospital·N/A·NCT06590714·150 enrolled

Acute Myeloid Leukemia1 trial

GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly

Completed·FFrench Innovative Leukemia Organisation·Phase 3·NCT00925873·303 enrolled

Labor Induction1 trial

Second Trimester Labor Induction

Withdrawn·JJohns Hopkins University·Phase 1·NCT00592215

Radiation Therapy1 trial

Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy

Not yet recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT07076914·58 enrolled

Gastrointestinal1 trial

The Effect of Prucalopride Succinate on Gastrointestinal Motility After Laparoscopic Gastrectomy : Prospective Double Blind Case-control Study

Completed·GGangnam Severance Hospital·N/A·NCT05966246·106 enrolled

Bursitis1 trial

Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment

Completed·UUniversidad Autonoma de Nuevo Leon·Phase 2·NCT01205477·58 enrolled

Non-Small Cell Lung Cancer1 trial

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

Recruiting·TThe Third Xiangya Hospital of Central South University·Phase 2·NCT07138755·35 enrolled

Diabetic Neuropathy1 trial

Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy

Completed· Roche logo

Roche·Phase 2·NCT00496457·159 enrolled

Trial1 trial

A Trial of Generic Substitution of Antiepileptic Drugs

Unknown status·IIRCCS National Neurological Institute "C. Mondino" Foundation·Phase 4·NCT02429596·200 enrolled

Unspecified3 trials

Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B

Completed·HHospital Clinic of Barcelona·Phase 1·NCT01923610·24 enrolled

A First-in-Human Study With XAB05 in Healthy Subjects

Completed·XXenothera SAS·Phase 1·NCT05307406·25 enrolled

Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

Completed· Biogen logo

Biogen·Phase 1·NCT01420458·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Experimental. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Experimental compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Experimental. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Biogen

Experimental

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q1 2028

Q4 2029

Trials by Indication[1]

Peritonitis2 trials

Esophageal Cancer1 trial

Osteoporosis1 trial

Post-cesarean Pain1 trial

Clinical Trial1 trial

Radiotherapy1 trial

Allergic Rhinitis1 trial

Patients With Locally Advanced Rectal Cancer1 trial

Lung Adenocarcinoma1 trial

Efficacy1 trial

Congestive Heart Failure1 trial

Follicular Lymphoma1 trial

Chronic Hepatitis1 trial

Albuminuria1 trial

Septic Shock1 trial

Cutaneous Leishmaniasis1 trial

Tolerance1 trial

Rotator Cuff Tear1 trial

Acute Myeloid Leukemia1 trial

Labor Induction1 trial

Radiation Therapy1 trial

Gastrointestinal1 trial

Bursitis1 trial

Non-Small Cell Lung Cancer1 trial

Diabetic Neuropathy1 trial

Trial1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News